Clinical Trials Browser

Phase 2 × Has results × Neoplasms, Squamous Cell × Clear all

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00542308 2023-08-03

Zalutumumab in Non-curable Patients With SCCHN

Phase 2 Completed

90 enrolled 10 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT02837042 2022-06-21

Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

Phase 2 Terminated

6 enrolled 10 charts

Genitourinary

Penile Neoplasms, Neoplasms, Squamous Cell

NCT03937791 2021-04-13

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Phase 2 Terminated

1 enrolled 8 charts

Neoplasms, Squamous Cell, Papillomavirus Infections

NCT01111058 2020-04-07

Everolimus Versus Placebo in Head and Neck Cancer

Phase 2 Terminated

52 enrolled 13 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01581970 2019-09-11

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Phase 2 Completed

7 enrolled 9 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00661427 2018-01-11

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 2 Completed

61 enrolled 8 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00591149 2017-06-14

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Phase 2 Terminated

16 enrolled 5 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Neoplasms, Squamous Cell

NCT00485485 2012-08-07

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

Phase 2 Completed

7 enrolled 7 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00229723 2009-08-04

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

224 enrolled 21 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

Clinical Trials

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Zalutumumab in Non-curable Patients With SCCHN

Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Everolimus Versus Placebo in Head and Neck Cancer

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma